Trials / Completed
CompletedNCT01911221
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate the immunogenicity and safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | rMenB+OMV NZ | Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2013-07-30
- Last updated
- 2017-06-08
- Results posted
- 2014-10-31
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01911221. Inclusion in this directory is not an endorsement.